The difficult trials.


addition of the NK1-receptor antagonist, casopitant (day 1–3), to a combination of ondansetron (day 1–3) plus dexamethasone (day 1) was investigated in patients receiving moderately emetogenic chemotherapy [4]. In a subpopulation (n = 123) treated with oxaliplatin-based chemotherapy, the 0–120-h complete response rate (no emesis and no need for rescue… (More)
DOI: 10.1159/000193221


Cite this paper

@article{Herrstedt2009TheDT, title={The difficult trials.}, author={J\orn Herrstedt}, journal={Onkologie}, year={2009}, volume={32 1-2}, pages={7-8} }